Spatial multi-omics and AI for decoding tumor heterogeneity: implications for target discovery and therapy resistance
- 1Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, United States
Abstract
Tumor heterogeneity remains a major bottleneck for effective cancer therapy because many determinants of target expression, biomarker performance, and treatment resistance are spatially organized within the tumor ecosystem. Bulk molecular profiling averages these signals across cell populations, whereas dissociation-based single-cell approaches disrupt the tissue architecture that shapes cell state, signaling, and drug access. Spatial multi-omics addresses these limitations by mapping transcriptomic, proteomic, metabolomic, and epigenomic features in situ, while AI enables integration of these modalities with histology, spatial coordinates, and clinical outcomes. Current evidence suggests that graph-based and neighborhood-aware models are most useful for spatial domain detection and niche mapping, whereas multimodal and histology-based models require stronger external validation before clinical deployment. In this review, we examine how spatial multi-omics and AI are redefining tumor heterogeneity as a translational variable in oncology. We focus on target discovery, patient stratification, and resistance biology. We also discuss major barriers to clinical translation, including platform bias, FFPE compatibility, assay cost, molecular coverage, segmentation and registration errors, limited benchmarking, domain shift, and the need for independent multicenter validation.
Related
- Decoding Human Milk Lactoprotein Heterogeneity: From Genetic Variation to Proteoforms and Peptidoforms in a Comparative Mammalian Context
- Editorial: Decoding the gut-brain axis: implications for neurodegenerative disease therapies
- Decoding pyroptosis at single-cell resolution: heterogeneity, microenvironment remodeling and potential translational insights
- Spatial transcriptomics reveals microenvironmental heterogeneity in osteoarthritic subchondral bone
- 1170 Spatial transcriptomics identifies immune heterogeneity in estrogen receptor positive postpartum breast cancer
BibTeX
@article{raheem2026spatial,
title = {{Spatial multi-omics and AI for decoding tumor heterogeneity: implications for target discovery and therapy resistance}},
author = {Kayode Raheem and Swathi Sai Yakasiri and Chittibabu Guda},
journal = {Neoplasia (New York, N.Y.)},
year = {2026},
month = oct,
doi = {10.1016/j.neo.2026.101385},
url = {https://doi.org/10.1016/j.neo.2026.101385},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Spatial multi-omics and AI for decoding tumor heterogeneity: implications for target discovery and therapy resistance
AU - Kayode Raheem
AU - Swathi Sai Yakasiri
AU - Chittibabu Guda
PY - 2026
DA - 2026/10/24
JO - Neoplasia (New York, N.Y.)
DO - 10.1016/j.neo.2026.101385
UR - https://doi.org/10.1016/j.neo.2026.101385
AB - Tumor heterogeneity remains a major bottleneck for effective cancer therapy because many determinants of target expression, biomarker performance, and treatment resistance are spatially organized within the tumor ecosystem. Bulk molecular profiling averages these signals across cell populations, whereas dissociation-based single-cell approaches disrupt the tissue architecture that shapes cell state, signaling, and drug access. Spatial multi-omics addresses these limitations by mapping transcriptomic, proteomic, metabolomic, and epigenomic features in situ, while AI enables integration of these modalities with histology, spatial coordinates, and clinical outcomes. Current evidence suggests that graph-based and neighborhood-aware models are most useful for spatial domain detection and niche mapping, whereas multimodal and histology-based models require stronger external validation before clinical deployment. In this review, we examine how spatial multi-omics and AI are redefining tumor heterogeneity as a translational variable in oncology. We focus on target discovery, patient stratification, and resistance biology. We also discuss major barriers to clinical translation, including platform bias, FFPE compatibility, assay cost, molecular coverage, segmentation and registration errors, limited benchmarking, domain shift, and the need for independent multicenter validation.
SN - 1522-8002
SN - 1476-5586
ER -